Kadmon Corp. LLC, of New York, said data from a phase Ib trial evaluating tesevatinib (formerly KD019), the company's oral tyrosine kinase inhibitor, in combination with Herceptin (trastuzumab, Roche AG) for the treatment of patients with HER2-positive metastatic breast cancer with brain metastases, showed that the combination appears to be well tolerated, and one heavily pretreated patient with brain metastases had prolonged stable disease with gradual discontinuation of steroids.